Please enter verification code
Confirm
Colorectal Cancer Demographics and Survival in a London Cancer Network
Cancer Research Journal
Volume 5, Issue 2, March 2017, Pages: 14-19
Received: Jun. 6, 2017; Accepted: Jun. 20, 2017; Published: Jul. 20, 2017
Views 2181      Downloads 157
Authors
Roy Gurprashad, Department of Colorectal Surgery, Croydon University Hospital, London, United Kingdom
Adil Khan, Department of Colorectal Surgery, Croydon University Hospital, London, United Kingdom
Alex Oldman, Department of Colorectal Surgery, Croydon University Hospital, London, United Kingdom
Clare Peckitt, Department of Colorectal Surgery, Croydon University Hospital, London, United Kingdom
Article Tools
Follow on us
Abstract
The purpose of this study was to examine whether a relationship exists between age, ethnicity, gender and survival of patients within a London Cancer Network. All patients with non metastatic colorectal cancer diagnosed and treated within the South West London Cancer Network between January 2001 and January 2006 were included for analysis. Consent was gained from all hospitals within the London Cancer Network, and data was subsequently requested from the Thames Cancer Registry. In total, 3151 patients were analysed. The results demonstrated that from 2003 there was a yearly increase in new cancer diagnosis. The ratio of male to female patients was approximately equal over the time period (51.5% male, 48.5% female). The overall mean patient age at diagnosis was 70.76 years. Asian, black and mixed race patients had better survival rates than white European patients (hazard ratios 0.96, 0.87, 0.96 respectively). Patients in the age cohort ‘50-59 years’ had a 5 year survival rate of 57.8 months (hazard ratio 1.63), whilst the ‘under 40 years’ age cohort had the longest 5 year survival rate of 67.4 months. When comparing tumour sites, patients with rectosigmoid tumours had the lowest 5 year survival rate (hazard ratio 1.12), and those with rectal tumours (n=816, hazard ratio 0.88) had the longest 5 year survival rate. Median and overall survival for all patients was 38.84 months and 42.3% respectively. Surgery with neoadjuvant therapy resulted in the longest 5 year survival rate at 62.8%. Surgery alone had a 5 year survival rate of 43%. The results could be used to help design a prognostic indicator tool as a means by which to assist clinicians in providing patients with information on survival outcomes.
Keywords
Colorectal Cancer, Patient Demographics, Cancer Survival Rates
To cite this article
Roy Gurprashad, Adil Khan, Alex Oldman, Clare Peckitt, Colorectal Cancer Demographics and Survival in a London Cancer Network, Cancer Research Journal. Vol. 5, No. 2, 2017, pp. 14-19. doi: 10.11648/j.crj.20170502.12
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Cancer Research UK (http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer; Last Accessed May 2017.
[2]
Department of Health (1997) Guidance on Commissioning Cancer Services. Improving Outcomes in Colorectal Cancer. The Manual. London: Department of Health.
[3]
Calman – Hine Report (1995) A Report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales. A Policy Framework for Commissioning Cancer Services The Calman – Hine Report. London: Department of Health.
[4]
Morris, E., Haward, R. A., Gilthorpe, M. S., Craigs, C. & Forman, D. (2006) The impact of the Calman-Hine report on the processes and outcomes of care for Yorkshire’s colorectal cancer patients. British Journal of Cancer, 95, 979–985.
[5]
Association of Coloproctology of Great Britain and Ireland (2007) Guidelines for the Management of Colorectal Cancer, 3rd edn. Avail- able at: http://www.acpgbi.org.uk/resources/guidelines (last accessed 7 June 2010).
[6]
Department of Health (2007) Manual of Cancer Service Standards. Available at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_ digitalassets/@dh/@en/documents/digitalasset/dh_4066453.pdf (last accessed May 2012).
[7]
Department of Health (2000). The NHS Plan. A plan for investment, a plan for reform. London: The Stationery Office.
[8]
Rho YS, et al. (2017)“Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer; An International Collaborative Study” Clin. Colorectal Cancer 2017.
[9]
American Cancer Society, Atlanta. “Colorectal Cancer Facts and Figures 2011-2013” www.cancer.org - American Cancer Society, 2017; 7.
[10]
Hargreaves MK. Baquet C. Gamshadzahi A, Diet, nutritional status, and cancer risk in Arnerican Blacks, Nutr Cancer 1989; 12: l-2.
[11]
R. Williams, et al. Colorectal Cancer in African Americans: An Update. Clin Trans Gastroenterol. 2016 Jul; 7 (7): e185.
[12]
Mayberry RM, Coates RJ, Hill HA. Determinants of black white differences in colon survival. J Natl Cancer Inst 1995. 87: 1686-93.
[13]
Mostafa G, Mathews BD, Norton HJ, Kercher KW, Sing RF, Heniford BT. (2004). Influence of Demographics on Colorectal Cancer. The American Surgeon. 2004, 70 (3): 259-264.
[14]
Kiefe CI. Race/ethnicity and cancer survival, JAMA 2002; 287: 2138-9.
[15]
Bhandari A, et al. Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the USA: a SEER-based analysis with comparison to other young-onset cancers. J Investing Med 2016; 0: 1-5.
[16]
York Health Economics Consortium. Bowel cancer services: costs and benefits. York: York Health Economics Consortium; 2007.
[17]
Chan AT, Giovannucci EL. Primary Prevention of Colorectal Cancer. Gastroenterology Jun 2010; 138 (6); 2029-2043 e2010.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186